Coya Therapeutics reports $3.6 million collaboration revenue for Q3 2025
Reuters
Nov 12
<a href="https://laohu8.com/S/COYA">Coya Therapeutics</a> reports $3.6 million collaboration revenue for Q3 2025
Coya Therapeutics Inc. reported collaboration revenues of $3.6 million for the three months ended September 30, 2025, primarily due to the recognition of $3.3 million in license revenue following FDA acceptance of its IND for a Phase 2 study. Research and development expenses were $2.9 million, up from $2.2 million in the same period last year, mainly due to increased clinical and internal research costs. General and administrative expenses rose to $2.6 million from $2.2 million. Net loss was $2.1 million, compared to a net loss of $4.0 million for the same period in 2024. As of September 30, 2025, cash and cash equivalents totaled $28.1 million. During the quarter, Coya announced FDA acceptance of its IND application for COYA 302 for ALS, received a $4.2 million milestone payment from Dr. Reddy's Laboratories, and closed a $23.0 million public offering, extending its cash runway into the second half of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112343663) on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.